Market
Number of countries adopting Gilead's generic HIV prevention injections by end of 2025?
2
Resolution / Starting Odds
Less than 50 countries • 25%
50 to 80 countries • 25%
81 to 120 countries • 25%
More than 120 countries • 25%
Reports from Gilead and health organizations tracking drug adoption
Story
New HIV Prevention Injections Offer Six Months Protection; 100% Effective, Gilead to Sell Generics Ahead of World AIDS Day
Dec 1, 2024, 04:00 PM
Recent advancements in HIV prevention include long-acting injections that provide protection for up to six months per shot. As World AIDS Day approaches, experts are evaluating the implications of these new tools in combating HIV. A study has shown that a twice-yearly injection was 100% effective in preventing HIV infections among women and nearly as effective in men. Pharmaceutical company Gilead has announced plans to sell affordable generic versions of the medication in 120 countries with high rates of HIV. Despite these advancements, experts emphasize the importance of equitable access and addressing adherence challenges to maximize the impact of HIV prevention efforts.
View original story
Similar markets
50 to 80 • 25%
More than 120 • 25%
81 to 120 • 25%
Less than 50 • 25%
60 to 90 countries • 25%
More than 90 countries • 25%
Fewer than 30 countries • 25%
30 to 60 countries • 25%
10 to 20 • 25%
More than 30 • 25%
Less than 10 • 25%
21 to 30 • 25%
None • 25%
1-3 Countries • 25%
4-6 Countries • 25%
More than 6 Countries • 25%
1-4 countries • 25%
15 or more countries • 25%
10-14 countries • 25%
5-9 countries • 25%
UK • 25%
USA • 25%
Other • 25%
South Africa • 25%
Less than 20% • 25%
More than 60% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 10 countries • 25%
6 to 10 countries • 25%
No countries • 25%
1 to 5 countries • 25%
Other • 25%
India • 25%
South Africa • 25%
United States • 25%